Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Overview

Early proof-of-concept of DNA-based NGS to detect gene fusions was demonstrated in a panel of breast cancer cell line and tissues [1]. However, detection of NTRK gene fusions by DNA-based NGS is complicated by the large intronic spaces within the genes, particularly for the NTRK3 gene. This can result in false negative results with DNA-based NGS platforms [2].

Figure 11: Overview of DNA- and RNA-based NGS

References

  1. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
  2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings